Search | Clinical Trials Finder

Conditions: Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
Interventions: nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions: BNT323, BNT327; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more

Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Lomvastomig; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Neoplasms by Site
Interventions: Relatlimab, Nivolumab, BMS-986213; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 1,482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 17
States / cities: La Jolla, California • Aurora, Colorado • Tampa, Florida + 14 more

Conditions: Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventions: Avelumab, Stereotactic ablative radiotherapy (SAR); Drug · Radiation
Lead sponsor: Megan Daly, MD; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions: RNDO-564, Pembrolizumab; Drug
Lead sponsor: Rondo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more

Conditions: Bladder Cancer
Interventions: B-701, Pembrolizumab; Drug
Lead sponsor: Mark Pomerantz, MD; Other
Eligibility: 18 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent High Grade Glioma
Interventions: MVR-C5252; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Advanced Solid Tumor
Interventions: LM-108, An Anti-PD-1 Antibody; Drug
Lead sponsor: LaNova Medicines Limited; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Ocala, Florida • Indianapolis, Indiana • Canton, Ohio + 3 more

Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions: PLX3397, Pembrolizumab; Drug · Biological
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more

Conditions: Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Interventions: PF-07263689, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Duarte, California • New York, New York

Conditions: Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
Interventions: Radiation Therapy, Cetuximab, Chemotherapy, Immunotherapy; Radiation · Drug
Lead sponsor: Loren Mell, MD; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: PF-06801591, Bacillus Calmette-Guerin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 44
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 24 more

Conditions: Advanced Melanoma
Interventions: Botensilimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fullerton, California • Santa Monica, California + 4 more

Conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions: Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Solid Tumors
Interventions: BI 1831169, anti-PD-1 antibody; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: BI 765063, Ezabenlimab, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Interventions: DRP-104, atezolizumab; Drug · Biological
Lead sponsor: Dracen Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more

Conditions: Relapsed or Refractory Classical Hodgkin Lymphoma
Interventions: Sabestomig (AZD7789); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 101 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
Interventions: Ibrutinib, Idelalisib, Laboratory Biomarker Analysis, Pembrolizumab; Drug · Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Metastatic Colorectal Cancer
Interventions: AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more

Conditions: Merkel Cell Carcinoma, Small Cell Lung Cancer
Interventions: XmAb18087, XmAb18087 ± Pembrolizumab; Biological · Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy (5 days), Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 3
States / cities: San Diego, California • Portland, Oregon

Search by objective public record fields.

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

QUantitative Assessment of Swallowing After Radiation (QUASAR)

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

The Seven Trial: Exploiting the Unfolded Protein Response

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)